Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BRCA1 mutation higher in Ashkenazi women:

This article was originally published in Clinica

Executive Summary

The BRCA1 gene mutation 185delAG may account for 16% of breast cancers and 39% of ovarian cancers diagnosed in Ashkenazi women under the age of 50, new research suggests (Nature Genetics, vol 11. The deletion carrier rate was found to be at least three times higher in Ashkenazi women than in the general US population.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel